Brief: Gain Therapeutics - Sees Existing Cash, Cash Equivalents, Marketable Securities To Enable It To Fund Operating Expenses & Capex Requirements Into 2024
08/08/2022 13:22
Aug 8 (Reuters) - Gain Therapeutics Inc GANX.O :
* GAIN THERAPEUTICS, INC. REPORTS SECOND QUARTER 2022
FINANCIAL
RESULTS AND BUSINESS UPDATE
* GAIN THERAPEUTICS - SEES EXISTING CASH, CASH EQUIVALENTS,
MARKETABLE SECURITIES TO ENABLE IT TO FUND OPERATING EXPENSES &
CAPEX REQUIREMENTS INTO 2024
* GAIN THERAPEUTICS - REVENUES WERE $0.95 MILLION FOR
THREE-MONTH
PERIOD ENDED JUNE 30, 2022 VERSUS $0.89 MILLION FOR SAME PERIOD
IN 2021
* GAIN THERAPEUTICS INC QTRLY GAAP BASIC AND DILUTED NET
LOSS PER
SHARE WAS $0.43
Source text for Eikon: ID:nGNX35Q5JQ
Further company coverage: GANX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Gain Therapeutics
See all newsU.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil,
Gain Therapeutics climbs on narrower-than-expected quarterly loss
Gain Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Gain Therapeutics Q2 net loss per share narrows as R&D expenses fall